Seeking Alpha

Boston Scientific's (BSX -1.1%) Infinion 16 Percutaneous Lead, a spinal cord stimulation...

Boston Scientific's (BSX -1.1%) Infinion 16 Percutaneous Lead, a spinal cord stimulation (SCS) therapy, performed well in a trial and significantly reduced pain in patients when used with the Precision Plus SCS System. Boston's Clik Anchor also demonstrated good results in reducing the migration, or movement, of SCS leads. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)